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Abstract 
Over 50% of patients are already taking blood pressure-lowering therapy on hospital admission for 
acute stroke. An individual patient data meta-analysis from randomized controlled trials was 
undertaken to determine the effect of continuation versus temporarily stopping pre-existing 
antihypertensive medication in acute stroke. Key databases were searched for trials against the 
following inclusion criteria: randomized design; stroke onset ≤48 hours; investigating the effect of 
continuation versus stopping pre-stroke antihypertensive medication; follow up of ≥2 weeks. Two 
randomized controlled trials were identified and included in this meta-analysis of individual patient 
data from 2860 patients ≤48 hours of acute stroke. Risk of bias in each study was low. In adjusted 
logistic regression and multiple regression analyses (using random effects), we found no significant 
association between continuation of pre-stroke antihypertensive therapy (versus stopping) and risk 
of death or dependency at final follow-up: Odds Ratio 0.96 (95% Confidence Intervals 0.80 to 
1.14). No significant associations were found between continuation (versus stopping) of therapy and 
secondary outcomes at final follow-up.  Analyses for death and dependency in pre-specified 
subgroups revealed no significant associations with continuation versus temporarily stopping 
therapy, with the exception of patients randomised ≤12 hours, in whom a difference favoring 
stopping treatment met statistical significance. We found no significant benefit with continuation of 
antihypertensive treatment in the acute stroke period. Therefore, there is no urgency to administer 
pre-existing antihypertensive therapy in the first few hours or days following stroke, unless 
indicated for other comorbid conditions. 
 
 
Keywords 
Stroke, Hypertension, Antihypertensive therapy, Blood pressure, Individual patient data meta-
analysis, Randomized controlled trials 
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Introduction 
Elevated blood pressure (BP) is common in patients presenting with acute stroke, of whom 
approximately 75% have a BP >140/90 mmHg [1,2]. The natural history is for BP to decline 
spontaneously over the subsequent several days. Elevated BP is associated with poor outcome, 
whether defined as recurrent stroke, early death, or death and disability several months after stroke 
onset [3-5]. There is however, limited and conflicting evidence regarding the benefits of BP 
lowering treatment in acute stroke, with some large studies reporting near positive effects on 
functional outcome [6], but others reporting neutral [7,8,9], or near negative results [10]. Thus, 
current meta-analyses and international guidelines state that the optimal management of elevated 
BP in acute stroke remains uncertain [11-15].  
 
An important, and frequently encountered dilemma faced by clinicians in the management of acute 
stroke is how to manage pre-existing antihypertensive medication. Over 50% of patients presenting 
with acute stroke are already taking BP lowering medication, usually for the treatment of 
hypertension, but also for other co-morbidities such as heart failure, ischemic heart disease, atrial 
fibrillation and prostatic hypertrophy. Although BP lowering medication should be continued in the 
long term for secondary prevention [16], the effect of its continued use in the immediate post stroke 
period remains unclear; further, acute stroke may be complicated by dysphagia thereby 
complicating administration of oral drugs. Continuation of therapy could theoretically be beneficial 
in helping reduce early recurrence, avoiding rebound increases in BP and heart rate with cessation 
of therapy, and in ensuring that antihypertensives are continued on hospital discharge. Conversely, 
temporarily stopping treatment may be advantageous: many patients do not regularly take their 
medication, and thus administration in hospital could lead to abrupt, and potentially harmful 
declines in BP; dehydration and hypovolemia are not uncommon following stroke, and further BP 
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lowering may be detrimental; stopping BP lowering medication may increase blood flow through 
collateral vessels, and increase blood supply to the potentially salvageable ischemic penumbra; 
administration of oral medication in the presence of dysphagia may lead to aspiration.  
 
Two large randomized controlled trials were undertaken to address this question: COSSACS 
(Continue Or Stop post Stroke Antihypertensives Collaborative Study) [17] and  ENOS (Efficacy of 
Nitric Oxide) [7]. Both were neutral for the primary outcome of 2-week death or dependency 
(COSSACS) [17] and 3-month modified Rankin scale (mRS) shit (ENOS) [7], though COSSACS 
was substantially underpowered to detect an effect on primary outcome. Our aim was to perform an 
individual patient meta-analysis of data from available randomized controlled trials (RCTs) to 
determine the effect of continuation versus temporarily stopping existing antihypertensive 
medication in the acute stroke period; an important and common clinical problem. The use of data 
from individual patients allows analyses to be performed within prospectively determined 
subgroups, larger than those in individual trials, enhancing statistical power.  
Methods 
Search Strategy and Selection Criteria 
We followed the guidelines for reports of meta-analyses of RCTs according to the PRISMA 
statement (Table S1) and used a pre-specified review protocol [18]. We searched Medline, 
EMBASE, and the Cochrane library (from inception to October 2015) for RCTs comparing the 
effect of continuing or temporarily stopping pre stroke antihypertensive medications combining text 
terms, and where appropriate MeSH terms for stroke, and antihypertensive medication. An example 
search strategy can be found in (Table S2). We limited our search to humans, RCTs, meta-analyses 
and systematic reviews. We did not apply language restrictions. We also searched reference lists of 
included papers and systematic reviews, and relevant review articles.  
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Study Selection and Data Extraction 
We defined the following inclusion criteria: 
1) Randomized design with a follow up of ≥2 weeks 
2) Investigating the effect of continuing versus stopping (for at least 1 week) pre-existing anti-
hypertensive medication in those with acute stroke (recruited <48 hours of symptom onset) 
3) Outcomes of interest including at least one of: death; disability (mRS or equivalent); stroke 
recurrence; neurological deterioration (change in National Institute of Health Stroke 
Severity score (NIHSS), or equivalent); other vascular events. 
 
Two investigators screened the titles and abstracts and excluded all papers not meeting the criteria 
by consensus. The same investigators evaluated the remaining studies as full papers. Authors of the 
papers were then contacted to ascertain willingness to be included, and agreement to provide 
necessary data for this individual patient data meta-analysis. 
 
Definitions of risk factors, sub-groups at baseline, and outcomes were agreed prior to analysis of 
any of the trials. Pre-specified subgroups included: age (≤70 years, >70); sex; ethnicity (Caucasian, 
Asian, other); smoking status; atrial fibrillation (AF); diabetes; previous stroke; BP medications 
(angiotensin converting enzyme inhibitor (ACE-I), angiotensin two receptor antagonist (ARA), 
renin inhibitor, beta receptor antagonist, calcium channel blocker (CCB), diuretic, alpha receptor 
antagonist, centrally acting agent); number of BP medications (1, 2, 3, 4, >4); feeding status (Oral 
feeding, No oral feeding); Systolic BP (SBP; <140, 140 to 159, 160 to 180, >180mmHg); NIHSS 
(<15, >15); stroke type (ischemic, hemorrhagic); stroke syndrome as per Oxford Community Stroke 
Project classification (OCSP) (lacunar syndrome – LACS, partial anterior circulation syndrome - 
PACS, total anterior circulation syndrome – TACS, posterior circulation syndrome – POCS); and 
time to randomization (≤12 hours, 13 to 24, 25 to 36, >36).  
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The primary outcome was death or dependency, as measured using the mRS (0-2 defined as 
independent, 3-5 dependent, 6 death) when last measured during trial follow-up. Secondary 
outcomes at the end of the defined treatment period included: death; recurrent stroke (defined as 
“recurrent stroke ischemic” or “recurrent stroke hemorrhagic” and recorded as a safety outcome at 7 
days by investigators in ENOS; taken from serious adverse event data in COSSACS); neurological 
deterioration (adjudicated by local investigators and defined as an increase from baseline NIHSS of 
≥4 points); and death or neurological deterioration. Secondary outcomes at the end of follow-up 
were collected in both studies by telephone interviews in those who were alive. Those who had died 
were identified from the National Health Service (NHS) register, and cause of death was taken from 
the death certificate. For deaths outside the United Kingdom, information was obtained via 
individual sites. Secondary outcomes included: death; stroke recurrence; cardiovascular events; any 
vascular events, health related quality of life (EuroQol (EQ) 5D HUS) and functional outcome 
(independence or dependence - mRS and Barthel Index). If any trial used the Scandinavian Stroke 
Scale to define baseline severity and neurological impairment, these were transformed into NIHSS 
scores according to a published algorithm [19]. Since the COSSACS trial defined dependency at six 
months according to three categories, (based on responses to three standardized questions- an 
approach previously validated for assessment of functional outcome in stroke) [20], rather than 
individual mRS scores, we used the same approach for ENOS in order to create a common long-
term functional outcome for this analysis. Categories were: Independent (mRS 0); Independent 
(mRS 1 to 2); dependent (mRS 3 to 5). 
 
The included studies were approved by the relevant ethics committees: COSSACS – Trent Research 
Ethics Committee MREC/02/4/051); ENOS – Trent Regional Ethics Committee – MREC/01/4/046. 
In both trials, informed consent from the patient, or if the patient lacked capacity, assent from a 
relative or legal representative (with confirmation of assent from the patient when able) was 
obtained for all participants.  
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Statistical Analysis  
For the purposes of a one-stage meta-analysis, individual patient data from both trials were merged 
in to a single database prior to further analysis. Data from both trials were checked prior to and post 
merging.  No imputation was used for missing data. Data are described as mean (standard 
deviation) for continuous data, median (interquartile range) for ordinal data, or frequency 
(percentage) for binary data. The effect of continuing pre stroke antihypertensive medication (in 
comparison to temporary stopping) on outcomes was assessed using ANCOVA (BP outcomes), 
multiple linear regression, ordinal logistic regression (OLR) or binary logistic regression 
(depending on whether data were continuous, ordinal or binary in nature). For most of the 
outcomes, our assumption of equal residual variance held true. Nonetheless, in order to use 
consistent analysis techniques for outcomes we applied mixed-effects models to all.  The results 
from these analyses are expressed as odds ratio (OR) or mean difference (MD), with 95% 
confidence intervals. Outcomes analysed using mean difference were BP, NIHSS, EQ-5D, EQ-VAS 
and Barthel Index. The effect of treatment on the primary outcome was assessed in pre-specified 
subgroups in all patients. These subgroup analyses were performed by adding an interaction term to 
a mixed-effects OLR model.  Analysis of time to death was undertaken using a mixed-effects Cox 
proportional hazards regression model and a Kaplan-Meier plot used as a visual representation of 
time to death.  All analyses were adjusted using source trial as a random effect. Regression analyses 
were also adjusted for age, sex, baseline stroke severity (NIHSS) and mean SBP as fixed effects. 
All analyses were performed using SAS version 9.3. Statistical significance was set at p<0.05.  
 
HYPE201607982R2 
 
 
9 
Results 
Results of Search 
Figure 1 shows the study selection process. Of 2588 studies identified on the initial search, two 
(COSSACS – ISRCTN89712435, and ENOS – ISRCTN99414122) fulfilled the inclusion criteria. 
Chief investigators of both studies (TGR and PMB, respectively) were collaborators in this review 
and agreeable for the original datasets to be analysed. This meta-analysis of individual patient data 
from the COSSACS and ENOS trials includes data from 2860 patients with acute stroke (within 48 
hours of symptom onset), recruited from 222 sites in 23 countries across 5 continents.  
Description of Included Studies 
COSSACS was a UK multicenter prospective randomized open, blinded endpoint trial that assigned 
763 non-dysphagic stroke patients to either continue or stop antihypertensive medication for 14 
days using a secure web-based randomisation system [17]. Patients and clinicians who randomly 
assigned patients and administered treatment were unmasked to group allocation. ENOS was a 
partial factorial international randomized controlled trial where adult patients with acute ischemic 
stroke or ICH, and elevated BP (140 to 220mmHg) were randomized via a secure web-based 
randomization system to receive a GTN patch or no GTN patch for one-week (administered single 
blind), and in a subset of patients on pre-stroke antihypertensive medication, to continue or stop this 
medication for one week (open label) [21]. The primary and main secondary outcomes were 
collected centrally at day 90 by an assessor in each country who was blinded to treatment. Data 
from all 2097 ENOS participants was included in this meta-analysis.  A summary of characteristics 
of the two studies is shown in Table 1, and details of the primary and secondary outcome measures 
in Table S3.
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Risk of Bias and Quality Assessment 
All studies were assessed for quality using the Cochrane Collaboration ‘risk of bias’ tool, which 
considers the risk of selection, performance, detection, attrition and reporting bias [22]; the risk of 
bias in each domain being low for each study. 
Patient Characteristics 
Across the two trials, 1432 patients were randomized to continue pre-stroke antihypertensive 
medication, and 1428 were randomized to stop antihypertensive medication temporarily for the 
acute and sub-acute stroke periods. Recruited patients were similar to those recruited to stroke 
services with 52.4% male, a mean age of 73 years. Baseline characteristics across the two trial 
cohorts were broadly similar (Table S4). Differences in participants’ ethnic origins are to be 
expected given the geographical location of centres involved in the two studies, and the observed 
differences in stroke type, and severity are at least in part, likely to be a consequence of the 
COSSACS trial excluding patients with dysphagia (more common in severe strokes). COSSACS 
did not have blood pressure limits whereas ENOS included only patients with SBP 140-220 mmHg. 
Blood Pressure Profiles 
SBP and Diastolic BP (DBP) fell in both randomized groups from recruitment to day seven, with a 
steeper decline seen in those who continued their anti-hypertensive medication (Figure S1). A 
significant difference in SBP was present by Day 1 and in DBP from Day 2; the absolute difference 
in BP was maximal at day 7. 
Effect of Continuation of Antihypertensive Therapy on Outcomes  
ENOS and COSSACS recorded outcomes at end of treatment at seven and 14 days, respectively. 
Logistic and multiple regression analyses adjusted for trial, age, sex, baseline stroke severity, and 
baseline SBP showed no significant association between continuation of antihypertensive treatment 
(versus stopping it) and stroke recurrence; neurological impairment, death or neurological 
deterioration; or death at end of treatment (Table 2). A significant association was observed 
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between continuation of treatment and recurrent ischemic stroke, but no such association was 
reported with recurrent ICH, nor with recurrent stroke of any type (ICH and ischemic stroke 
combined). No heterogeneity was observed when assessed by stroke type (ischemic stroke or ICH) 
(Table S5). 
 
With the exception of the Barthel Index (measured at 14 days in COSSACS and 90 days in ENOS), 
end-of-trial outcomes were measured at 180 and 90 days in the COSSACS and ENOS participant 
cohorts. There was no significant difference in the distribution of scores across mRS categories at 
the end of trial, between the continue versus stop groups (Figure 2). In adjusted mixed-effect 
logistic and multiple regression models, no significant association was found between continuation 
of antihypertensive treatment and end of trial death, death or dependency (mRS>2), or composite 
vascular events (Table S5). No statistically significant associations were reported between 
continuation of treatment, and health utility scores (EQ 5D HUS), Barthel Index scores, or self-
reported quality of life using the EQ VAS (Table S5).  Analysis of time to death using a mixed-
effects cox proportional hazards model (visually represented on a Kaplan-Meier plot) showed no 
difference in mortality in the continue group (Figure S2). An OLR analysis of the mRS, by trial, 
showed that in both ENOS and COSSACS there was no significant difference in outcome between 
the continue versus stop groups (Figure 3). In subgroup analyses, patients who stopped 
antihypertensives within 12 hours of stroke onset had less death or dependency (Figure 4). No 
significant association was noted in any of the other pre-specified subgroups, though in the majority 
of subgroups, point estimates of odds ratios favored stopping pre-existing antihypertensive therapy.
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Discussion 
Around half of patients presenting with acute stroke are on pre-existing anti-hypertensive 
medication. Whether to continue or stop this medication in the acute and sub-acute stroke period is 
a commonly encountered clinical dilemma, and a particular challenge in light of neutral results from 
previous RCTs and partly conflicting data from other acute stroke BP-lowering trials. The results 
from this meta-analysis of individual patient data from two large RCTs suggest that continuation of 
pre-existing antihypertensive medication, versus temporarily stopping it, confers no significant 
benefit to patients in terms of short- or long-term outcomes following acute ischemic or 
hemorrhagic stroke, despite the fact that BP was significantly lower in the Continue group from 
days one to seven, and levels of BP declined more steeply. Analyses for the effect of continuing 
versus stopping antihypertensives on death or dependency, by our pre-defined subgroups, including 
effect by drug class, baseline BP, and stroke subtype, showed no obvious effect, with the exception 
of the subgroup randomized within 12 hours of stroke onset, in which continuation (versus 
stopping) of antihypertensives was significantly associated with risk of worse outcome. In the 
absence of any ongoing or planned studies further examining this question, the main implication for 
clinical practice is that in the acute stroke period, clinicians should not rush to administer pre-
existing antihypertensive therapy, unless indicated by other comorbid conditions. Indeed, a 
reasonable approach would be to withhold BP lowering drugs until patients are medically and 
neurologically stable, and with a safe swallow or once enteral access is obtained. 
 
This is the first meta-analysis to address the question of whether to continue or temporarily stop 
pre-stroke antihypertensive medication, and our study has several strengths: the analysis included a 
wide range of stroke patients recruited from centres across 23 different countries, albeit 
predominantly Caucasian, with baseline characteristics broadly representative of those recruited to 
stroke services, thus ensuring generalizability of findings; the large sample size increased precision 
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and reliability of estimates; we used individual patient data, thus allowing us to perform analyses on 
large pre-defined subgroups, with higher numbers, and greater statistical power than in the 
individual trials. However, the power to detect a difference between the two groups in the primary 
outcome is less than 10%, and any future trial would need to recruit in excess of 10,000 patients. 
 
The neutral results on primary outcome reported in this review are in keeping with the findings of 
the two individual studies when considered separately. Furthermore, our findings are concordant 
with data from several acute stroke BP-lowering trials that reported no significant effect on 
functional or neurological outcomes, with initiation of BP lowering therapy in the acute stroke 
period [9,10,23,24].  Of course, our data are not directly comparable with such trials given that our 
study was concerned with pre-existing medication, rather than starting new antihypertensive 
therapy. Nonetheless, this meta-analysis found significantly lower BP profiles with steeper rates of 
decline in average BP over the first seven days in the continue versus stop groups. In fact, observed 
differences in SBP and DBP at day seven between the two randomized groups were greater than has 
been observed in some acute stroke BP lowering trials; -9.4mmHg for SBP and -5.1 for DBP in the 
Continue versus the Stop group. Despite these statistically significant and clinically relevant BP 
differences, we report no significant evidence of beneficial effect on short- or long-term outcomes 
with continuation of therapy.  
 
Effects on death and dependency were similar for the majority of our pre-defined subgroups, 
including all BP levels, stroke type (ICH or ischemic stroke, and OCSP class), and number and 
class of pre-stroke antihypertensive agents. However, in the subgroup randomized within 12 hours 
of stroke onset, a statistically significant association, favoring Stop was reported. There is no robust 
explanation for this result, particularly given that on day 0, the BP differences between continue and 
stop groups were minimal. It may reflect the play of chance but perhaps in the first few hours after 
stroke onset, and in the presence of impaired cerebral autoregulation [25], the penumbral, and 
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potentially salvageable tissue, is particularly vulnerable to the effects of BP lowering, with BP 
declines increasing risk of further ischemia, especially in the absence of therapeutic or spontaneous 
reperfusion where collateral blood flow is important. Or early continuation of medications may 
cause aspiration pneumonia in patients who have, or develop, dysphagia early after their stroke, as 
seen in ENOS. Conversely later after onset, the effects of BP lowering on an established ischemic 
core, with less potentially viable penumbral tissue, may be of less pathological and clinical 
consequence. Few acute stroke BP lowering studies have enrolled patients very early (within the 
first few hours) from stroke onset. However, results from a subgroup analysis of ENOS (those 
receiving BP-lowering treatment with GTN within six hours from stroke onset) [7], and the Rapid 
Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT) [26], where transdermal 
GTN was given within four hours (median 55 minutes) of stroke onset, are discordant with our 
findings, each suggesting benefit with very early BP lowering. Furthermore, the Intensive blood 
pressure reduction in acute cerebral hemorrhage (INTERACT-2) study of BP lowering within 6 
hours of ICH showed safety and borderline significant favorable outcomes in early BP lowering [6].  
  
Possible explanations for the lack of benefit with continuation of BP-lowering therapy are as 
follows: first, classes of antihypertensive drug may be important, with some exerting a beneficial 
and others, a detrimental effect. In this meta-analysis, the majority of patients were taking at least 
one drug exerting effects on the renin angiotensin system (ACE-I, ARA, or ß-receptor antagonist). 
Acute stroke trials have shown harm with ARA [27], and with ß-receptor antagonists [28]. 
Secondly, many patients do not regularly take their prescribed medication, and in hospital 
administration of BP-lowering medication may lead to abrupt, and potentially hazardous BP 
declines. Thirdly, administration of oral medication in those with impaired swallow may lead to 
aspiration and pneumonia, a hypothesis supported by the ENOS finding of higher rates of 
pneumonia in the continued group [7], but not in this meta-analysis, potentially due to the 
COSSACS trial excluding those with dysphagia. Fourthly, the effect of continuation of pre-stroke 
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BP-lowering medication may differ depending on pre-morbid BP levels, or presence or extent of an 
abrupt BP rise. In a recent observational study in 653 patients with acute ischemic stroke or ICH, 
Rothwell and colleagues found that SBP was substantially raised compared with last premorbid 
levels in ICH, but in acute ischemic stroke was much closer to the accustomed long-term pre-
morbid level [29]. The authors suggested that any benefits of BP-lowering therapy in acute stroke 
might be greater in those in whom the high post-event level is unaccustomed, and postulate that this 
may help explain the mostly neutral effects of BP lowering on outcome in acute ischemic stroke, 
compared with potential benefits observed in ICH. Though our subgroup analysis showed no 
difference in outcome in ischemic stroke and ICH subgroups, the numbers of ICH patients were low 
(284 patients), and we may therefore have not been able to detect an effect. Furthermore, as in most 
acute stroke BP trials, we do not have data on participant’s pre-stroke BP trends. Finally, BP 
variability (BPV) may be of prognostic significance in acute stroke as reported in a recent post-hoc 
analysis of the INTERACT 2 dataset [30]. Different antihypertensive agents exert differential 
effects of BPV, and thus, within individual BPV (unmeasured in this analysis) [31] and the effect of 
drug class on BPV may have had an unmeasured influence on outcome.  
 
Limitations 
This study also has potential limitations. The analysis is under-powered; any future trial would need 
to recruit in excess of 10,000 patients to detect a difference between the two groups in the primary 
outcome is less than 10%. Therefore, applying the conclusions to all sub-groups may not be 
appropriate. For example, detailed information was missing on large vessel occlusions and those 
who received acute revascularization procedures. In addition, selection bias may have arisen as both 
trials excluded patients with the following characteristics: very high SBP (> 200mmHg, or DBP 
>120 in COSSACS; >220 and >140 in ENOS); contraindications to stopping, or indications to 
continue antihypertensive therapy (plus definite indications or contraindications to nitrate therapy in 
ENOS); impaired consciousness, premorbid dependency (mRS >3); and patients expected to require 
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surgical intervention (albeit rates of significant carotid artery stenosis were low at 2.6%). In 
addition, COSSACS excluded those with dysphagia. Although statistical models were adjusted for 
several co-variables, residual confounding may still have occurred. Furthermore, both trials were, 
out of necessity, open label and performance bias cannot be excluded, although outcome assessors 
were masked to treatment allocation in both trials. Finally, there are limited data on patients 
recruited very early from stroke onset, which should be a focus of future acute stroke BP research. 
  
Perspectives 
This meta-analysis addresses an important and frequently encountered dilemma for clinicians, and 
represents all available randomized data on the subject.  There are unlikely to be further available 
data in the near future and our findings are likely to inform future national and international acute 
stroke guidelines.  We found no significant benefit with continuation of treatment in the acute 
stroke period. Therefore, there is no urgency to administer pre-existing antihypertensive therapy in 
the first few hours or days following stroke, and not until the patient is medically stable and has a 
safe swallow or established enteral access, unless of course indicated by other comorbid conditions. 
Given recent findings of safety and possible benefit with initiation of BP-lowering therapy within 6 
hours of ICH, and recent sub-group analyses in the ischemic stroke population suggesting that very 
early BP lowering may be beneficial, future acute stroke BP studies should aim to recruit patients 
very early from stroke onset, in order to determine the effect of BP lowering in the first few hours.  
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Novelty and Significance 
What Is New? 
An individual patient data meta-analysis from randomized controlled trials to determine the effect 
of continuation versus temporarily stopping pre-existing antihypertensive medication in acute 
stroke. 
What Is Relevant? 
No significant association between continuation of pre-stroke antihypertensive therapy (versus 
stopping) and risk of death or dependency at final follow-up. Analyses in pre-specified subgroups 
revealed no significant associations with continuation versus temporarily stopping therapy, with the 
exception of patients randomised ≤12 hours, in whom a difference favoring stopping treatment met 
statistical significance. 
Summary 
There is no urgency to administer pre-existing antihypertensive therapy in the first few hours or 
days following stroke, until the patient is medically stable and has a safe swallow or established 
enteral access, unless indicated by other comorbid conditions. 
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Figure Legends 
Figure 1: Study Selection Process 
 
Figure 2. Modified Rankin scale at end of trials. Comparison by mixed-effects ordinal logistic 
regression. OR 0.97 (95% CI 0.84-1.12, 2p=0.68). 
 
Figure 3. Forest plot of functional outcome (mRS) by trial 
Comparison by ordinal logistic regression. 
 
Figure 4. Forest plot of functional outcome (mRS) by pre-specified subgroups 
ICH, Intracerebral Hemorrhage; LACS, lacunar syndrome; PACS, partial anterior circulation 
stroke; TACS, total anterior circulation stroke; POCS, posterior circulation stroke; ACEI, 
angiotensin converting enzyme inhibitor. Analysis undertaken using a mixed-effects ordinal logistic 
regression model. 
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Table 1. Characteristics of trials comparing continuing versus stopping pre-stroke 
antihypertensive medication during acute stroke  
Characteristics COSSACS ENOS 
Size 763 2097 
Recruitment time window 
(hrs) 
< 48 < 48 
Length of treatment (days) 14 7 
Length of follow-up (days) 180 90 
SBP range (mmHg) > 100 140 - 220 
Major exclusions Need for antihypertensive agents Need for GTN or 
antihypertensive agents 
Countries 1 23 
Centres 49 173 
COSSACS: Continue Or Stop post-Stroke Antihypertensives Collaborative Study; ENOS: Efficacy 
of Nitric Oxide and Stroke trial; GTN: glyceryl trinitrate; SBP: systolic blood pressure 
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Table 2. Functional outcome and vascular events: continue versus stop pre-stroke 
antihypertensive medication. Percentage for continue versus stop; comparison by mixed-
effects logistic regression, or mixed-effects multiple regression, adjusted for trial as a random 
effect and age, sex, severity, and baseline systolic blood pressure as fixed effects. Odds ratios 
below one and mean differences below zero favor continuing pre-stroke antihypertensive 
medication. 
Outcomes 
Odds ratio/MD (95% Confidence 
Interval) P for significance 
 
End-of-treatment (14 days in 
COSSACS, 7 days in ENOS) 
  
Death  1.04 (0.64, 1.69) 0.87 
Recurrence of stroke (ischemic stroke or 
intracerebral hemorrhage)  
1.41 (0.85, 2.34) 0.19 
Recurrence of stroke (ischemic) 2.27 (1.17, 4.39) 0.015 
Recurrence of stroke (hemorrhagic) 0.35 (0.09, 1.31) 0.12 
Death or Deterioration  0.86 (0.68, 1.09) 0.21 
Neurological Impairment (worsening of 
scores on the NIHSS by ≥4 from 
baseline)* 
0.38 (-0.12, 0.87) 0.75 
Death or Institutionalization 1.10 (0.93, 1.30) 0.26 
 
End-of-trial (180 days in COSSACS, 90 
days in ENOS) 
  
Death 1.06 (0.84, 1.35) 0.63 
Modified Rankin Scale (mRS) ‡ 0.94 (0.84, 1.12) 0.68 
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Outcomes 
Odds ratio/MD (95% Confidence 
Interval) P for significance 
Death or dependency (mRS > 2)  0.96 (0.80, 1.14) 0.62 
Barthel Index †  -3.20 (-6.08, -0.33) 0.23 
EuroQoL-5D health utility status -0.03 (-0.06, 0.00) 0.31 
EuroQoL-visual analogue scale -2.00 (-4.48, 0.48) 0.31 
Vascular events ʇ 0.87 (0.71, 1.08) 0.21 
 
* In ENOS, NIHSS derived from Scandinavian Stroke Scale (20) 
† Measured at 14 days in COSSACS, and 90 days in ENOS 
‡ Categories derived from the International Stroke Trial questionnaire: Independent (mRS 0); 
Independent (mRS 1 to 2); Dependent (mRS 3 to 5). 
ʇ Composite of vascular death, non-fatal stroke, and non-fatal myocardial infarction 
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Table S1: PRISMA Checklist 
 
Section/topic  # Checklist item  
Reported 
on page 
#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data 
sources; study eligibility criteria, participants, and interventions; study appraisal and 
synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3-4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
5-7 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), 
and, if available, provide registration information including registration number.  
5 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics 
(e.g., years considered, language, publication status) used as criteria for eligibility, giving 
rationale.  
5-7 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched.  
5 
Search  8 Present full electronic search strategy for at least one database, including any limits used, 
such that it could be repeated.  
5  
(Fig 1) 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic 
review, and, if applicable, included in the meta-analysis).  
5-6 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators.  
6 
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Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and 
any assumptions and simplifications made.  
6 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis.  
6 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  7-8 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2) for each meta-analysis.  
7-8 
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Section/topic  # Checklist item  
Reported 
on page 
#  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies).  
6 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified.  
7-8 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram.  
8-9  
(Fig 2) 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, 
PICOS, follow-up period) and provide the citations.  
9-10 
(Table 1) 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment 
(see item 12).  
11 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple 
summary data for each intervention group (b) effect estimates and confidence intervals, 
ideally with a forest plot.  
11-18 
(Tables 2-
4; Figures 
3-6) 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
14-15 
(Figures 
4,6) 
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Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  11 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression [see Item 16]).  
18 
(Figure 7) 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy 
makers).  
19-23 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias).  
20 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and 
implications for future research.  
23-24 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of 
data); role of funders for the systematic review.  
27 
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Table S2: Example Search Strategy 
“Stroke” OR “cerebr* vascular disease” OR “cerebr* ischaemia” OR “intracerebr* 
haemorrhage” OR “cerebr* haemorrhage” OR  “brain isch*” OR “brain haemorrhage” 
AND “blood pressure” OR “BP” OR “hypertension” OR “antihypertensive” AND “stop” 
OR “cease” OR “continue” AND “outcome*” OR “prognos*” OR “mortality” OR “death” 
OR “dependenc*” OR “disability” OR “neurological deterioration” OR “functional 
depenc*” 
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Table S3: Primary and secondary outcome measures in the COSSACS and 
ENOS trials 
Continue Or Stop post-Stroke Antihypertensives Collaborative Study 
Primary Outcome 2 weeks Death and dependency 
(mRS>3) 
Early Secondary Outcomes  2 weeks NIHSS score increase or 
decrease by 4 points or 
more; 
Barthel Index; 
EQ-5D; 
EQ-VAS; 
Discharge destination; 
SAEs 
Late Secondary Outcomes 6 months Case fatality; 
Stroke recurrence; 
Health-related QoL; 
Functional status*; 
Place of residence 
Efficacy of Nitric Oxide Study 
Primary Outcome 90 days mRS shift 
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Early Secondary Outcomes 7 days Recurrent stroke; 
Neurological impairment on 
Scandinavian Stroke Scale; 
Death 
Late Secondary Outcomes 90 days Cognition (MMSE); 
Health related quality of 
life (EQ-5D), from which 
the health utility status 
was calculated [HUS]; 
EQ-VAS; 
Mood 
 
mRS: modified Rankin scale; NIHSS: National Institutes of Health Stroke Scale; EQ-
5D: EuroQol-5D; EQ-VAS: EuroQoL- Visual Analogue Scale; SAEs: Serious Adverse 
Events; QoL: Quality of Life; MMSE: Mini-Mental State Examination. 
*functional status (assessed by standardized questions to assess mRS category at 
telephone interview).  
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Table S4: Baseline characteristics of trial participants. 
Number (percentage) or mean (standard deviation). 
Characteristics 
COSSACS
* ENOS† All Continue Stop 
No. of participants 763 2097 2860 1432 1428 
Age (years) 73.95 
(10.78) 
72.89 
(11.18) 
73.17 
(11.08) 
73.49 
(11.11) 
72.86 
(11.05) 
Sex, Male (%) 426 (56.5) 1068 
(50.93) 
1494 
(52.4) 
738 
(51.75) 
756 
(53.05) 
Race-ethnicity (%)      
Caucasian 588 
(91.73) 
1824 
(86.98) 
2412 
(88.09) 
1202 
(87.55) 
1210 
(88.64) 
Asia 35 (5.46) 202 (9.63) 237 (8.66) 122 (8.89) 115 (8.42) 
Other 18 (2.81) 71 (3.39) 89 (3.25) 49 (3.57) 40 (2.93) 
Medical History (%)      
Hypertension 744 
(98.02) 
1994 
(95.09) 
2738 
(95.87) 
1370 
(95.87) 
1368 
(95.87) 
Diabetes mellitus 129 
(20.12) 
484 
(23.08) 
613 
(22.39) 
309 
(22.51) 
304 
(22.27) 
Hyperlipidemia 350 
(46.11) 
808 
(38.53) 
1158 
(40.55) 
568 
(39.75) 
590 
(41.35) 
Atrial fibrillation 156 
(20.45) 
566 
(26.99) 
722 
(25.24) 
382 
(26.68) 
340 
(23.81) 
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Characteristics 
COSSACS
* ENOS† All Continue Stop 
Previous stroke 150 
(19.76) 
416 
(19.84) 
566 
(19.82) 
275 
(19.24) 
291 
(20.39) 
TIA 140 
(18.45) 
352 
(16.79) 
492 
(17.23) 
255 
(17.84) 
237 
(16.61) 
Ischemic heart disease 152 
(20.03) 
523 
(24.94) 
675 
(23.63) 
332 
(23.23) 
343 
(24.04) 
Smoking, current 120 
(16.06) 
363 
(18.15) 
483 
(17.58) 
248 
(18.09) 
235 
(17.08) 
Rankin scale, pre-morbid 0 497 
(65.14) 
1413 
(67.38) 
1910 
(66.78) 
938 (65.5) 972 
(68.07) 
Antihypertensive agents pre-
stroke 
     
Angiotensin converting 
enzyme inhibitor 
316 
(41.69) 
999 
(47.64) 
1315 
(46.06) 
697 
(48.81) 
618 
(43.31) 
Angiotensin receptor 
antagonist 
112 
(14.78) 
337 
(16.07) 
449 
(15.73) 
207 (14.5) 242 
(16.96) 
Renin inhibitor - 4 (0.19) 4 (0.14) 3 (0.21) 1 (0.07) 
Beta receptor antagonist 272 
(35.88) 
820 (39.1) 1092 
(38.25) 
542 
(37.96) 
550 
(38.54) 
Calcium channel blocker 291 
(38.44) 
725 
(34.57) 
1016 
(35.6) 
486 
(34.06) 
530 
(37.14) 
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Characteristics 
COSSACS
* ENOS† All Continue Stop 
Diuretic 364 
(48.02) 
735 
(35.05) 
1099 
(38.49) 
552 
(38.66) 
547 
(38.33) 
Alpha receptor antagonist 61 (8.04) 146 (6.96) 207 (7.25) 110 (7.7) 97 (6.8) 
Centrally acting 4 (0.53) 32 (1.53) 36 (1.26) 22 (1.54) 14 (0.98) 
Other 0 (0) 23 (1.1) 23 (0.8) 15 (1.05) 8 (0.56) 
Number of antihypertensive 
agents 
     
1 299 (39.5) 915 
(43.63) 
1214 
(42.54) 
606 
(42.47) 
608 
(42.61) 
2 293 
(38.71) 
729 
(34.76) 
1022 
(35.81) 
505 
(35.39) 
517 
(36.23) 
3 130 
(17.17) 
335 
(15.98) 
465 
(16.29) 
233 
(16.33) 
232 
(16.26) 
4 33 (4.36) 93 (4.43) 126 (4.41) 70 (4.91) 56 (3.92) 
> 4 2 (0.26) 14 (0.67) 16 (0.56) 7 (0.49) 9 (0.63) 
Medications, other pre-stroke      
Statin 377 
(50.07) 
882 
(42.47) 
1259 
(44.49) 
620 
(43.79) 
639 
(45.19) 
Hemodynamic measures      
Systolic BP (mmHg) 149.39 
(22.36) 
167.08 
(18.78) 
162.38 
(21.28) 
161.53 
(21.28) 
163.22 
(21.25) 
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Characteristics 
COSSACS
* ENOS† All Continue Stop 
Diastolic BP (mmHg) 80.68 
(13.26) 
88.3 
(13.05) 
86.28 
(13.53) 
85.93 
(13.52) 
86.62 
(13.54) 
Pulse pressure (mmHg) 68.71 
(17.61) 
78.78 
(17.65) 
76.1 
(18.19) 
75.6 
(17.94) 
76.6 
(18.43) 
Systolic BP, peak (mmHg) 237.67 233.33 237.67 233.33 237.67 
Heart rate (bpm) 73.62 
(16.33) 
77.13 
(15.19) 
76.21 
(15.57) 
76.38 
(15.83) 
76.04 
(15.32) 
Rate-pressure product 
(mmHg.bpm) 
10988.71 
(2861.53) 
12880.29 
(2899.49) 
12385.07 
(3006.43) 
12354.94 
(3039.19) 
12415.23 
(2974.04) 
Stroke severity, NIHSS 5.53 
(4.44) 
11.55 
(5.78) 
9.95 
(6.07) 
10.14 
(6.1) 
9.77 (6.03) 
Stroke type/etiology (%)      
IS 690 
(93.12) 
1833 
(87.41) 
2523 
(88.9) 
1272 
(89.45) 
1251 
(88.35) 
ICH 38 (5.13) 246 
(11.73) 
284 
(10.01) 
138 (9.7) 146 
(10.31) 
Non stroke 13 (1.75) 18 (0.86) 31 (1.09) 12 (0.84) 19 (1.34) 
Stroke syndrome (%)      
Total anterior circulation 72 (9.56) 697 
(33.24) 
769 
(26.98) 
399 (28) 370 
(25.96) 
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Characteristics 
COSSACS
* ENOS† All Continue Stop 
Partial anterior circulation 312 
(41.43) 
702 
(33.48) 
1014 
(35.58) 
498 
(34.95) 
516 
(36.21) 
Posterior circulation 82 (10.89) 74 (3.53) 156 (5.47) 84 (5.89) 72 (5.05) 
Lacunar 287 
(38.11) 
624 
(29.76) 
911 
(31.96) 
444 
(31.16) 
467 
(32.77) 
Stroke etiology (if ischaemic) 
(%) 
     
Small vessel - 626 
(29.85) 
626 
(29.85) 
305 
(28.96) 
321 
(30.75) 
Large artery - 417 
(19.89) 
417 
(19.89) 
197 
(18.71) 
220 
(21.07) 
Cardioembolic - 507 
(24.18) 
507 
(24.18) 
277 
(26.31) 
230 
(22.03) 
Other - 330 
(15.74) 
330 
(15.74) 
170 
(16.14) 
160 
(15.33) 
Carotid stenosis, ipsilateral 
70-99% 
1 (0.13) 74 (3.53) 75 (2.62) 33 (2.3) 42 (2.94) 
Time to randomisation (hr) 
(%) 
     
<= 12 84 (11.34) 384 
(18.35) 
468 
(16.51) 
224 (15.8) 244 
(17.23) 
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Characteristics 
COSSACS
* ENOS† All Continue Stop 
13-24 315 
(42.51) 
571 
(27.28) 
886 
(31.26) 
444 
(31.31) 
442 
(31.21) 
25-48 342 
(46.15) 
1138 
(54.37) 
1480 
(52.22) 
750 
(52.89) 
730 
(51.55) 
Oral Feeding 763 (100) 1323 
(63.09) 
2086 
(72.94) 
1056 
(73.74) 
1030 
(72.13) 
 
Data presented as mean (SD) or n (%). 
BP, blood pressure; ICH, intracerebral hemorrhage; IS, ischemic stroke; NIHSS, 
National Institutes of Health Stroke Scale; TIA, transient ischemic attack 
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Table S5: Functional outcome and vascular events. 
Percentage for continue versus stop; comparison by mixed-effects ANCOVA (using trial as a random effect, blood pressure 
outcomes only), mixed-effects logistic regression, or mixed-effects multiple regression. Regression models were adjusted for trial 
as a random effect and age, sex, severity, systolic blood pressure as fixed effects. Odds ratios below one and mean differences 
below zero favor continuing pre-stroke antihypertensive medication. 
Outcomes COSSACS ENOS 
All 
OR/MD 
(95% CI) p 
IS 
OR/MD 
(95% CI) p 
ICH 
OR/MD 
(95% CI) p 
 Continue Stop Continue Stop       
Patients 379 384 1053 1044       
End of treatment  outcomes (14 days in COSSACS, 7 days in ENOS) 
Death, end of 
treatment (%) 
4 (1.11) 7 (1.97) 34 (3.24) 27 (2.59) 1.04 (0.64, 
1.69) 
0.87 1.23 (0.73, 
2.07) 
0.44 0.53 (0.12, 
2.42) 
0.41 
Recurrence, 
during 
treatment (%) 
8 (2.11) 8 (2.08) 30 (2.86) 18 (1.73) 1.41 (0.85, 
2.34) 
0.19 1.4 (0.8, 
2.46) 
0.24 1.33 (0.28, 
6.21) 
0.72 
Ischemic (%) 5 (1.32) 4 (1.04) 25 (2.37) 9 (0.86) 2.27 (1.17, 
4.39) 
0.015 2.1 (1.05, 
4.19) 
0.036 - - 
Hemorrhagic 
(%) 
1 (0.26) 0 (0) 2 (0.19) 8 (0.77) 0.35 (0.09, 
1.31) 
0.12 0.18 (0.02, 
1.54) 
0.12 0.57 (0.08, 
3.77) 
0.55 
Unknown (%) 2 (0.53) 4 (1.04) 3 (0.28) 1 (0.1) 0.97 (0.28, 
3.39) 
0.97 0.91 (0.23, 
3.68) 
0.9   
Death or 
Deterioration 
(%) 
72 (20.22) 82 (23.43) 108 (10.32) 107 (10.28) 0.86 (0.68, 
1.09) 
0.21 0.91 (0.7, 
1.17) 
0.45 0.55 (0.27, 
1.14) 
0.11 
Impairment, 
NIHSS* (/42) 
3.77 (5.34) 3.47 (4.98) 9.17 (6.59) 8.73 (6.47) 0.38 (-0.12, 
0.87) 
0.75 0.16 (-0.38, 
0.7) 
0.77 0.45 (-1.17, 
2.08) 
0.29 
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Outcomes COSSACS ENOS 
All 
OR/MD 
(95% CI) p 
IS 
OR/MD 
(95% CI) p 
ICH 
OR/MD 
(95% CI) p 
Systolic BP 140.04 
(21.91) 
153.48 
(23.75) 
145.58 
(24.52) 
155.08 
(23.88) 
-10.63 (-
12.53, -8.72) 
< 
0.0001 
-10.31 (-
12.4, -8.22) 
< 
0.0001 
-9.21 (-
15.52, -2.9) 
0.007 
Diastolic BP 76.11 
(13.66) 
84.11 
(13.84) 
80.03 
(14.72) 
85.06 
(14.34) 
-5.88 (-7.02, 
-4.73) 
< 
0.0001 
-5.71 (-6.97, 
-4.46) 
< 
0.0001 
-5.37 (-9.19, 
-1.55) 
0.004 
Death or 
Institution (%) 
186 (49.08) 188 (48.96) 662 (62.87) 603 (57.76) 1.1 (0.93, 
1.3) 
0.26 1.11 (0.92, 
1.34) 
0.27 1.19 (0.69, 
2.05) 
0.52 
End of trial outcomes (180 days in COSSACS, 90 days in ENOS) 
Death, end of 
trial (%) 
32 (8.79) 30 (8.38) 167 (15.9) 146 (14.02) 1.06 (0.84, 
1.35) 
0.63 1.18 (0.91, 
1.54) 
0.22 0.9 (0.46, 
1.77) 
0.76 
4-level mRS‡ 
mean(SD) 
1.31 (1.04) 1.3 (1.01) 1.76 (0.79) 1.74 (0.76) 0.97 (0.84, 
1.12) 
0.68 0.98 (0.84, 
1.16) 
0.85 0.77 (0.48, 
1.23) 
0.27 
mRS > 2 (%) 164 (43.27) 163 (42.45) 689 (65.43) 672 (64.37) 0.96 (0.8, 
1.14) 
0.62 0.97 (0.8, 
1.17) 
0.74 0.76 (0.41, 
1.42) 
0.39 
Barthel Index ʇ  76.94 
(30.56) 
78.44 
(30.18) 
58.1 
(40.81) 
61.94 
(39.4) 
-3.2 (-6.08, -
0.33) 
0.23 -2.93 (-6.12, 
0.26) 
0.16 -2.35 (-
11.64, 6.93) 
0.9 
Barthel Index < 
60 (%) ʇ 
82 (23.1) 80 (22.92) 425 (40.83) 365 (35.27) 1.15 (0.95, 
1.4) 
0.15 1.16 (0.94, 
1.43) 
0.18 1.18 (0.65, 
2.11) 
0.59 
EQ-5D HUS 0.68 (0.32) 0.7 (0.3) 0.41 (0.4) 0.44 (0.4) -0.03 (-0.06, 
0) 
0.31 -0.03 (-0.06, 
0.01) 
0.31 -0.02 (-0.11, 
0.07) 
0.81 
EQ-VAS 62.64 
(22.76) 
63.18 
(23.57) 
51.77 
(32.4) 
54.2 
(31.59) 
-2 (-4.48, 
0.48) 
0.31 -2.54 (-5.31, 
0.22) 
0.12 3.07 (-4.87, 
11) 
0.44 
Vascular event 
(%) [6] 
39 (10.29) 50 (13.02) 162 (15.38) 167 (16) 0.87 (0.71, 
1.08) 
0.21 0.94 (0.75, 
1.18) 
0.6 0.68 (0.35, 
1.35) 
0.27 
Lost to follow-up 
(%) 
18 (4.75) 29 (7.55) 3 (0.28) 3 (0.29) 0.56 (0.31, 
1.04) 
0.067 0.57 (0.23, 
1.39) 
0.22 - - 
* NIHSS was derived from Scandinavian Stroke Scale scores in ENOS 
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† Barthel Index measured at 14 days in COSSACS, and 90 days in ENOS 
‡ mRS categories derived from the IST questionnaire as follows: Independent (mRS 0); Independent (mRS 1 to 2); dependent 
(mRS 3 to 5). 
ʇ  Composite of vascular death, non-fatal stroke, and non-fatal myocardial infarction 
EQ-5D HUS: Health utility score calculated form the EuroQoL, health related quality of life questionnaire (EQ-5D); EQ-VAS: self-
rated health state, rated from 0 (worst health), to 100 (best imaginable health); ICH: Intracerebral hemorrhage; IS: ischemic 
stroke; IST: International stroke trial; mRS: modified Rankin scale; OR: odds ratio 
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Figure S1: Blood pressure profile over the first seven days of treatment. 
Comparison by t test with Bonferroni adjustment 
DBP: diastolic blood pressure; MD: mean difference between Stop and Continue 
groups; SBP: systolic blood pressure; SD: standard deviation 
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Figure S2. Kaplan-Meier curve for death. 
Comparison by mixed-effects Cox regression. HR 1.06 (95% CI 0.86- 1.29, 2p= 0.61). Analysis of time to death undertaken using 
a mixed-effects cox proportional hazards model; Kaplan-Meier plot used as a visual representation of time to death. 
 
